title: Combination chemotherapy of heptaplatin, paclitaxel and 5-fluorouracil in patients with advanced gastric cancer: a pilot study.
abstract: OBJECTIVE
  To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
  
  
  METHODS
  Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m(2) iv on day 1, heptaplatin 400 mg/m(2) iv on day 2 and 5-fluorouracil 800 mg/m(2) on day 2 approximately 4 were administered and the regimen was repeated every 3 weeks.
  
  
  RESULTS
  The median age of the patients was 60 years (range: 32 approximately 74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26 approximately 8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48 approximately 6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26 approximately 17.44). A median of 3 cycles (range: 1 approximately 7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life-threatening complication of pneumonia.
  
  
  CONCLUSIONS
  The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed.
authors.affiliation: Department of Internal Medicine, College of Medicine, Hanyang University, Seoul, Korea. ahnmj@hanyang.ac.kr
authors.forename: Myung-Ju
authors.initials: MJ
authors.lastname: Ahn
authors.forename: Ho-Suck
authors.initials: HS
authors.lastname: Oh
authors.forename: Jung-Hye
authors.initials: JH
authors.lastname: Choi
authors.forename: Young-Yeul
authors.initials: YY
authors.lastname: Lee
authors.forename: In-Soon
authors.initials: IS
authors.lastname: Kim
authors.forename: Il-Young
authors.initials: IY
authors.lastname: Choi
authors.forename: Oh Young
authors.initials: OY
authors.lastname: Lee
authors.forename: Ho-Soon
authors.initials: HS
authors.lastname: Choi
authors.forename: Sung-Joon
authors.initials: SJ
authors.lastname: Kwon
references.citation: Am J Clin Oncol. 1999 Dec;22(6):580-6
references.pmid: 10597742
references.citation: J Clin Oncol. 1992 Apr;10(4):541-8
references.pmid: 1548519
references.citation: J Clin Oncol. 2004 Jan 1;22(1):23-30
references.pmid: 14665611
references.citation: Cancer Chemother Pharmacol. 1998;41(2):109-16
references.pmid: 9443623
references.citation: J Clin Oncol. 2000 Jul;18(14):2648-57
references.pmid: 10894863
references.citation: Cancer. 1999 Oct 1;86(7):1109-15
references.pmid: 10506693
references.citation: Br J Cancer. 2000 Aug;83(4):458-62
references.pmid: 10945491
references.citation: Cancer. 1993 Jun 15;71(12):3813-8
references.pmid: 8508349
references.citation: Ann Oncol. 1994 Feb;5(2):189-90
references.pmid: 8186165
references.citation: Cancer. 1999 Jan 15;85(2):295-301
references.pmid: 10023695
references.citation: J Clin Oncol. 1997 Jan;15(1):261-7
references.pmid: 8996151
references.citation: Cancer Res Treat. 2003 Apr;35(2):117-22
references.pmid: 26680924
references.citation: Cancer. 1993 Jul 1;72(1):37-41
references.pmid: 8508427
references.citation: Cancer Res Treat. 2002 Apr;34(2):77-83
references.pmid: 26680846
references.citation: Br J Cancer. 1995 Mar;71(3):587-91
references.pmid: 7533517
references.citation: Cancer Chemother Pharmacol. 1995;37(1-2):1-6
references.pmid: 7497577
references.citation: Oncology. 2000 Apr;58(3):191-7
references.pmid: 10765119